Bortezomib Waverley 3
As listed in the register: Bortezomib Waverley 3,5 mg poeder voor oplossing voor injectie
3,5 mg · poeder voor oplossing voor injectie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Bortezomib
- Made by
- Waverley Pharma Europe Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (BORTEZOMIB). It describes the substance, not this exact product.
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells.
The 26S proteasome is a large protein complex that degrades ubiquitinated proteins.
Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-09
Safety of the active substance
From the US prescribing label for the same active substance (BORTEZOMIB). It describes the substance, not this exact product.
- Bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol.
- Reactions have included anaphylactic reactions [ see Adverse Reactions (6.1) ].
- Fatal events have occurred with intrathecal administration of bortezomib for injection.
- Patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions.
The most commonly reported (>20%) adverse reactions overall were nausea (52%), diarrhea (52%), fatigue (39%), peripheral neuropathies (35%), thrombocytopenia (33%), constipation (30%), vomiting (29%), and anorexia (21%).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States17 matching products
European UnionNo exact match for this strength and form
Spain22 matching products
- BORTEZOMIB ACCORD 3,5 mg · polvo para solución inyectable2 makers
- BORTEZOMIB ALTAN 3.5 mg · polvo para solución inyectable
- BORTEZOMIB AUROVITAS 3.5 mg · polvo para solución inyectable
- BORTEZOMIB BAXTER 3,5 mg · polvo para solución inyectable
- BORTEZOMIB CHEM AFFAIRS 3,5 mg · polvo para solución inyectable
- BORTEZOMIB CIPLA 3.5 mg · polvo para solución inyectable
- BORTEZOMIB COMBIX 3,5 mg · polvo para solución inyectable
- BORTEZOMIB DR. REDDYS 3,5 mg · polvo para solución inyectable
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Waverley Pharma Europe Limited |
|---|---|
| Active substance | Bortezomib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 3,5 mg |
| Form | poeder voor oplossing voor injectie |
| Classification | L01XG01 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik, subcutaan gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Bortezomib Waverley 3,5 mg poeder voor oplossing voor injectie |
| RVG | 122457 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.